Cite
HARVARD Citation
Blauvelt, A. et al. (2017). Extension of ustekinumab maintenance dosing interval in moderate‐to‐severe psoriasis: results of a phase IIIb, randomized, double‐blinded, active‐controlled, multicentre study (PSTELLAR). British journal of dermatology. pp. 1552-1561. [Online].